scholarly journals Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson’s Disease: Dawn of a New Era

2017 ◽  
Vol 21 (5) ◽  
pp. 569-573 ◽  
Author(s):  
Roger A. Barker ◽  
Malin Parmar ◽  
Lorenz Studer ◽  
Jun Takahashi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Dopamine Neurons ◽  
New Era ◽  
Human Trials

Ethical Criteria for Human Trials of Stem-Cell-Derived Dopaminergic Neurons in Parkinson's Disease

2015 ◽  
Vol 6 (1) ◽  
pp. 52-60 ◽  
Author(s):  
Samia A. Hurst ◽  
Alex Mauron ◽  
Shahan Momjian ◽  
Pierre R. Burkhard
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Dopaminergic Neurons ◽  
Human Trials ◽  
Ethical Criteria

Stem cell-derived dopamine neurons for brain repair in Parkinson’s disease

2010 ◽  
Vol 5 (2) ◽  
pp. 267-278 ◽  
Author(s):  
Rosemary A Fricker-Gates ◽  
Monte A Gates
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Dopamine Neurons ◽  
Brain Repair

scholarly journals Stem Derived Dopamine Neurons: Will They Replace DBS as the Leading Neurosurgical Treatment for Parkinson’s Disease?

2021 ◽  
pp. 1-9
Author(s):  
Roger A. Barker ◽  
Anders Björklund ◽  
Steven J. Frucht ◽  
Clive N. Svendsen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Stem Cell ◽  
Dopamine Neurons ◽  
Positive Outcomes ◽  
Critical Pathway ◽  
The Future ◽  
Neurosurgical Treatment

The use of stem cell derived dopamine neurons for treating patients with Parkinson’s disease has now evolved to the first in human clinical trials. In this debate, we argue that assuming these trials give positive outcomes that this therapy will supercede DBS as the neurosurgical treatment of choice for PD patients in the future given it is a one-off therapy that repairs a critical pathway in the parkinsonian brain.

Stem cell deficiency in Parkinson's disease

2005 ◽  
Vol 32 (06) ◽  
Author(s):  
GU Höglinger ◽  
P Rizk ◽  
WH Oertel ◽  
EC Hisch
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell

scholarly journals α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Abeer Dagra ◽  
Douglas R. Miller ◽  
Min Lin ◽  
Adithya Gopinath ◽  
Fatemeh Shaerzadeh ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neuronal Activity ◽  
Dopaminergic Neurons ◽  
Prolonged Exposure ◽  
D2 Receptor ◽  
Neuronal Firing ◽  
Dopamine Neurons ◽  
Loss Of Function ◽  
Therapeutic Implications

AbstractPathophysiological damages and loss of function of dopamine neurons precede their demise and contribute to the early phases of Parkinson’s disease. The presence of aberrant intracellular pathological inclusions of the protein α-synuclein within ventral midbrain dopaminergic neurons is one of the cardinal features of Parkinson’s disease. We employed molecular biology, electrophysiology, and live-cell imaging to investigate how excessive α-synuclein expression alters multiple characteristics of dopaminergic neuronal dynamics and dopamine transmission in cultured dopamine neurons conditionally expressing GCaMP6f. We found that overexpression of α-synuclein in mouse (male and female) dopaminergic neurons altered neuronal firing properties, calcium dynamics, dopamine release, protein expression, and morphology. Moreover, prolonged exposure to the D2 receptor agonist, quinpirole, rescues many of the alterations induced by α-synuclein overexpression. These studies demonstrate that α-synuclein dysregulation of neuronal activity contributes to the vulnerability of dopaminergic neurons and that modulation of D2 receptor activity can ameliorate the pathophysiology. These findings provide mechanistic insights into the insidious changes in dopaminergic neuronal activity and neuronal loss that characterize Parkinson’s disease progression with significant therapeutic implications.

Sign in / Sign up

Export Citation Format

Share Document